Table 4.
Proportion of patients with treatment‐related adverse events (other serious or other significant) by PT (safety analysis population)
| SOC | PT | n = 129 | |
|---|---|---|---|
| n | (%) | ||
| All | 83 | 64.3 | |
| Death | 0 | ||
| Other serious | 4 | 3.1 | |
| Appendicitis | 1 | 0.78 | |
| Brain abscess | 1 | 0.78 | |
| Meningitis bacterial | 1 | 0.78 | |
| Colon cancer | 1 | 0.78 | |
| IgA nephropathy | 1 | 0.78 | |
| Tubulointerstitial nephritis | 1 | 0.78 | |
| Other significant | 15 | 11.6 | |
| Nasopharyngitis | 3 | 2.3 | |
| Influenza | 1 | 0.78 | |
| Cellulitis | 1 | 0.78 | |
| Folliculitis | 1 | 0.78 | |
| Pharyngitis | 1 | 0.78 | |
| Pyelonephritis | 1 | 0.78 | |
| Subcutaneous abscess | 1 | 0.78 | |
| Pneumonia bacterial | 1 | 0.78 | |
| Lung infection | 1 | 0.78 | |
| Upper respiratory tract inflammation | 1 | 0.78 | |
| Asthma | 1 | 0.78 | |
| Interstitial lung disease | 1 | 0.78 | |
| Pleural effusion | 1 | 0.78 | |
| Hepatic function abnormal | 2 | 1.6 | |
| Neutropenia | 1 | 0.78 |
IgA, immunoglobulin A; PT, preferred term; SOC, system organ class.